Filtered By:
Condition: Heart Failure

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 11296 results found since Jan 2013.

Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study Brief Reports
Conclusions— Female patients with atrial fibrillation had higher ischemic stroke rates compared with male patients, but the relative effects of apixaban compared with aspirin on both ischemic stroke and bleeding were similar in men and women.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lip, G. Y. H., Eikelboom, J., Yusuf, S., Shestakovska, O., Hart, R. G., Connolly, S., on behalf of the AVERROES Investigators Tags: Other anticoagulants, Thrombosis risk factors Brief Reports Source Type: research

N‐terminal pro‐B‐type natriuretic peptide and the risk of stroke and transient ischaemic attack: the Rotterdam Study
ConclusionsHigher NT‐proBNP is associated with incident stroke in men and women and with incident TIA only in women. These associations are independent of clinical heart disease preceding cerebrovascular disease.
Source: European Journal of Neurology - January 9, 2015 Category: Neurology Authors: M. L. P. Portegies, M. Kavousi, M. J. G. Leening, M. J. Bos, A. H. Meiracker, A. Hofman, O. H. Franco, P. J. Koudstaal, M. A. Ikram Tags: Original Article Source Type: research

National data on stroke outcomes in Thailand
In conclusion, the prevalence and outcomes of stroke in Thailand were comparable with other countries. The era of thrombolytic therapy has just begun in Thailand.
Source: Journal of Clinical Neuroscience - January 14, 2015 Category: Neuroscience Source Type: research

Risk of Stroke in Chronic Heart Failure Patients without Atrial Fibrillation: Analysis of the CORONA and GISSI-HF Trials.
CONCLUSIONS: -A small number of demographic and clinical variables identified a subset of HF patients without AF at high risk of stroke. PMID: 25810334 [PubMed - as supplied by publisher]
Source: Circulation - March 25, 2015 Category: Cardiology Authors: Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and GISSI-Heart F Tags: Circulation Source Type: research

Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA 2 DS 2 -VASc Score
ConclusionsLow-risk patients (CHA2DS2-VASc = 0 [male], 1 [female]) have a truly low risk for stroke and bleeding. With 1 additional stroke risk factor (CHA2DS2-VASc = 1 [male], = 2 [female]), there was a significant increase in event rates (particularly mortality) if nonanticoagulated.
Source: Journal of the American College of Cardiology - April 6, 2015 Category: Cardiology Source Type: research

Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry
The objective of the present prospective study, using data from 2008, was to evaluate the prevalence of AA (atrial fibrillation/flutter) in patients with stroke and the impact of implementing AF guidelines. Methods: The prevalence of AA was studied in patients diagnosed with stroke from January 1 to December 31, 2008 in the population-based Stroke Registry of Brest, France (total population, 363,760 according to the 2008 census, with 295,553 aged 15 years or older). Guidelines implementation was assessed in terms of antithrombotic therapy (VKA, antiplatelet agent, none), and the CHADS2 (Congestive heart failure, Hypertens...
Source: BMC Geriatrics - June 11, 2015 Category: Geriatrics Authors: Virginie JannouSerge TimsitEmmanuel NowakFrançois RouhartPhilippe GoasFrançois-Mathias MerrienIrina Viakhireva-DovganyukAnne Tirel-BadetsArmelle Gentric Source Type: research

A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation
The objective of this review is to provide an overview of modern AF stroke prevention with a focus on tailored treatment strategies. Biomarkers and genetic factors have been proposed to help identify ‘high‐risk’ patients to be targeted for oral anticoagulation, but ultimately their use must be balanced against that of more simple and practical considerations for everyday use. Current guidelines have directed focus on initial identification of ‘truly low‐risk’ patients with AF, that is those patients with a CHA2DS2‐VASc [congestive heart failure, hypertension, age ≥75 years (two points), diabetes mellitus, ...
Source: Journal of Internal Medicine - March 21, 2016 Category: Internal Medicine Authors: G. Y. H. Lip, T. Potpara, G. Boriani, C. Blomström‐Lundqvist Tags: Review Source Type: research

Effect of prestroke antiplatelets use on first‐ever ischaemic stroke severity and early outcome
ConclusionsOur findings provide further evidence supporting modest benefit of AP therapy on the course and outcome of first‐ever ischaemic stroke. Further large studies are needed to confirm this effect.
Source: International Journal of Clinical Practice - March 31, 2016 Category: Internal Medicine Authors: J. P. Bembenek, M. Niewada, M. Karlinski, A. Czlonkowska Tags: Original Paper Source Type: research

Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation.
Abstract Atrial fibrillation (AF) is a common arrhythmia increasing the risk of morbidity and adverse outcomes (stroke, heart failure, death). AF is found in 1-2% of the general population, with increasing prevalence with aging. Its exact epidemiological profile is incomplete and underestimated, because 10-40% of AF patients (particularly the elderly) can be asymptomatic ("clinically silent or subclinical AF"), with occasional electrocardiographic diagnosis. The research interest on silent AF has increased by the evidence that its outcome is no less severe, in terms of risks of stroke and death, than that for symp...
Source: Vascular Pharmacology - May 15, 2016 Category: Drugs & Pharmacology Authors: Boriani G, Pettorelli D Tags: Vascul Pharmacol Source Type: research

P-008 Evaluating Racial/Ethnic Disparity in Endovascular Thrombectomy Outcome for Acute Stroke Patients: 4,763 patients using Premier data 2011 to 2015
ConclusionsThere were no differences in hospital outcome among races/ethnicities in endovascular thrombectomy outcomes for acute stroke patients in the Premier data. Racial/ethnic disparities play role for patients’ selection not for patients’ outcome in endovascular thrombectomy.DisclosuresS. Park: None. M. Pilot: None. M. Alexander: 1; C; Consultant for Stryker Neurovascular, Medtronic, and Penumbra, Inc. A. Rosengart: None.
Source: Journal of NeuroInterventional Surgery - July 28, 2016 Category: Neurosurgery Authors: Park, S., Pilot, M., Alexander, M., Rosengart, A. Tags: Oral poster abstracts Source Type: research

Effect of Milrinone Infusion on Pulmonary Vasculature and Stroke Work Indices: A Single-Center Retrospective Analysis in 69 Patients Awaiting Cardiac Transplantation
ConclusionMilrinone improved left ventricular stroke work indices to a greater extent than right ventricular stroke work indices and had beneficial effects on right ventricular net input impedance, predominantly via augmentation of left ventricular stroke volume and passive unloading of the pulmonary circuit. Patients who had the worst biventricular performance benefited the most from chronic milrinone infusion.
Source: American Journal of Cardiovascular Drugs - March 28, 2017 Category: Cardiology Source Type: research

Intermediate-term rates of stroke following cardiac procedures: the Nationwide Readmissions Database (P4.305)
Conclusions:Using a large, nationally representative database of inpatient admissions from 2013, we found that 90-day stroke rates are higher after cardiac procedures compared to non-cardiac procedures and non-surgical admissions. However, these rates are likely lower than previously reported.Disclosure: Dr. Stein has nothing to disclose. Dr. Thaler has nothing to disclose. Dr. Liang has nothing to disclose. Dr. Tuhrim has nothing to disclose. Dr. Dhamoon has nothing to disclose. Dr. Dhamoon has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Stein, L., Thaler, A., Liang, J., Tuhrim, S., Dhamoon, A., Dhamoon, M. Tags: Neuroepidemiology: Cerebrovascular Disease I Source Type: research

Heart Failure and Stroke
AbstractPurposeIschemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk in HF, its risk stratification, and stroke prevention in these patients.Recent FindingsStroke risk stratification in HF patients remains an important issue. Recently, the CHA2DS2-VASc score, originally developed to predict stroke ...
Source: Current Heart Failure Reports - July 30, 2018 Category: Cardiology Source Type: research

Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
CONCLUSIONS: Overall, results of secondary analyses indicate that the recommended dosing strategy for each of the DOACs produces a consistent anticoagulant effect across a diverse patient population, including those at increased risk of stroke or bleeding. PMID: 30081727 [PubMed - in process]
Source: Adv Data - August 9, 2018 Category: Epidemiology Authors: Stacy ZA, Richter SK Tags: Ther Adv Cardiovasc Dis Source Type: research

Heart Failure and Stroke
AbstractPurposeIschemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk in HF, its risk stratification, and stroke prevention in these patients.Recent FindingsStroke risk stratification in HF patients remains an important issue. Recently, the CHA2DS2-VASc score, originally developed to predict stroke ...
Source: Current Heart Failure Reports - October 1, 2018 Category: Cardiology Source Type: research